Dermata therapeutics announces closing of $3.5 million private placement priced at-the-market under nasdaq rules

Dermata raises approximately $7.8 million in gross proceeds since may 2024 - expected to fund its operations into the second quarter of 2025 san diego, ca / accesswire / september 17, 2024 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 1,912,569 shares of common stock (or pre-funded warrant in lieu thereof) and accompanying series a warrants to purchase up to 1,912,569 shares of common stock and short-term series b warrants to purchase up to 1,912,569 shares of common stock at a purchase price of $1.83 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying series warrants priced at-the-market under the rules of the nasdaq stock market. the gross proceeds from the offering were approximately $3.5 million, prior to deducting placement agent's fees and other offering expenses payable by the company.
NDAQ Ratings Summary
NDAQ Quant Ranking